Available Until 5/4/2023

Surveillance powered by Diagnostics

Activity Description

Join CIDRAP-ASP for a webinar discussing the importance of surveillance for qualifying and quantifying antimicrobial resistance (AMR), and learn about the challenges of conducting surveillance in low and middle-income settings. We will also discuss how improving utilization of current diagnostic and surveillance methods can inform local, regional, and global policy, and how new technologies will enable improved adoption and tracking.

Target Audience

This program has been designed to meet the educational needs of physicians and pharmacists.

Learning Objectives

At the completion of this activity, the participant will be better able to:

  • Describe the current diagnostic and surveillance tools available in resource-limited settings.
  • Use surveillance data to connect with policy actions.
  • Explain the importance of improving laboratory capacity and diagnostic testing for the collection and reporting of AMR surveillance data.


Moderator: Marnie Peterson, PharmD, PhD, Outreach Coordinator, CIDRAP

Elvira Garza González, PhD, Faculty of Medicine, Autonomous University of Nuevo León

Carlos Arturo Álvarez Moreno, MD, PhD, Infectious Diseases Specialist, National University of Colombia

CME/CE Accreditation

Release Date: May 4, 2022
Expiration Date: May 4, 2023

ACPE Credit Designation (Pharmacist CE)

This activity is jointly provided by ProCE, LLC, and CIDRAP (Center for Infectious Disease Research and Policy). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-22-155-H01-P has been assigned to this home study, knowledge-based activity. This CE activity is approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ProCE, LLC and Clinical Care Options, LLC (CCO) require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE and CCO policy. ProCE and CCO are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Marnie Peterson, PharmD, PhD reports having co-ownership of Perfectus Biomed.
Carlos Alvarez-Moreno, MD, MSc, PhD, FIDSA has no relevant conflicts of interest to report.
Elvira Garza González, PhD reports receiving consultant, advisor, speaker fees from BioMerieux and Pfizer.
Kristine Moore, MD, MPH has no relevant conflicts of interest to report.
Maya Peters, MPH has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Kristine Moore, MD, MPH.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


This CE activity is supported by an educational grant from BD (Becton, Dickinson, and Company).

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.